
Developmental-stage biopharmaceutical company Silo Pharma, Inc. (NASDAQ:SILO) shares are trading higher on Friday.
The company has announced a collaboration with Kymanox to develop a specialized subcutaneous insertion device for SP-26, its ketamine-loaded implant aimed at treating fibromyalgia and chronic pain.